Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Usana Health Sciences (USNA) over the last 16 years, with Q3 2025 value amounting to $145.3 million.

  • Usana Health Sciences' Cash & Equivalents fell 6016.62% to $145.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.3 million, marking a year-over-year decrease of 6016.62%. This contributed to the annual value of $181.8 million for FY2024, which is 4498.88% down from last year.
  • Per Usana Health Sciences' latest filing, its Cash & Equivalents stood at $145.3 million for Q3 2025, which was down 6016.62% from $151.3 million recorded in Q2 2025.
  • In the past 5 years, Usana Health Sciences' Cash & Equivalents registered a high of $364.9 million during Q3 2024, and its lowest value of $145.3 million during Q3 2025.
  • In the last 5 years, Usana Health Sciences' Cash & Equivalents had a median value of $261.2 million in 2021 and averaged $262.2 million.
  • As far as peak fluctuations go, Usana Health Sciences' Cash & Equivalents surged by 3282.67% in 2021, and later plummeted by 6016.62% in 2025.
  • Over the past 5 years, Usana Health Sciences' Cash & Equivalents (Quarter) stood at $248.7 million in 2021, then increased by 15.97% to $288.4 million in 2022, then rose by 14.56% to $330.4 million in 2023, then crashed by 44.99% to $181.8 million in 2024, then dropped by 20.04% to $145.3 million in 2025.
  • Its last three reported values are $145.3 million in Q3 2025, $151.3 million for Q2 2025, and $179.6 million during Q1 2025.